The receptor status of breast cancer is determined through a test called immunohistochemistry (IHC). This test uses antibodies to detect the presence of ER and PR proteins in cancer tissue samples. The results are reported as a percentage, indicating the proportion of cancer cells that tested positive for these receptors.
